We aim to positively surprise our customers and partners with innovative approaches
In Conversation
It's important not to forget the significant contributions made by the pharmaceutical industry during the pandemic. The promises and commitments made by industry players and governments…
While generics continue to be a core focus, there has been a strategic shift towards emphasising innovation
Monica Bettencourt-Dias – Principal Investigator & Former Director, Gulbenkian Institute for Science (IGC)
The funding landscape for science in Portugal is facing challenges that stem from a decrease in overall investment and shifting priorities. Despite the evident role of…
Our broad, global portfolio includes products that help treat the top 10 leading causes of death globally, as determined by the WHO
We are committed to finding a balanced approach that considers both the imperative of enabling better health outcomes and the need for ensuring the sustainability of…
My vision for the presidency is centered on instilling pride within hospital pharmacists, encouraging a sense of accomplishment in their crucial role
It's crucial for all stakeholders, from promoters to investors, to comprehend the unique challenges and opportunities presented by the blue economy. The sector's success lies not…
My management style is based on betting everything on the people we have. I believe that having an efficient, motivated, and engaged team that works cross-functionally…
Our approach is characterized by collaboration and flexibility. We engage closely with our clients to comprehend their unique requirements and adapt our global offer accordingly. This…
I am optimistic that diabetes care will improve. The inequality of care in Europe and Portugal exists, and it is really important to plan how we…
A collaborative environment … can potentially position Portugal on par with Spain in the clinical research landscape within the next five years